Identifying biomarkers for effective immunotherapy in kidney cancer
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
This study is looking at how certain markers in tissue samples can help doctors figure out which patients with advanced kidney cancer are most likely to respond well to a specific immunotherapy treatment, so they can tailor the best care for each person.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10847506 on NIH RePORTER |
What this research studies
This research investigates how certain tissue-based biomarkers can predict the effectiveness of anti-PD-1 immunotherapy in patients with metastatic renal cell carcinoma (RCC). The team aims to understand the characteristics of T cells and the tumor microenvironment that influence treatment responses. By analyzing the expression of specific antigens and the presence of CD8+ T cells, the research seeks to identify which patients are most likely to benefit from this therapy. This could lead to more personalized treatment approaches for RCC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic renal cell carcinoma who are considering or currently undergoing anti-PD-1 therapy.
Not a fit: Patients with early-stage renal cell carcinoma or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help identify patients who are more likely to respond to immunotherapy, leading to improved treatment outcomes.
How similar studies have performed: Previous research has shown promising results in identifying biomarkers for immunotherapy responses in various cancers, suggesting that this approach may also be effective in RCC.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Choueiri, Toni — Dana-Farber Cancer Inst
- Study coordinator: Choueiri, Toni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.